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For most physicians, use of diagnostic tests is part of
daily routine. This paper focuses on their usefulness by
explaining the different measures of accuracy, the
interpretation of test results, and the implementation of a
diagnostic strategy. Measures of accuracy include sensitivity
and specificity. Although these measures are often
considered fixed properties of a diagnostic test, in reality
they are subject to multiple sources of variation such as the
population case mix and the severity of the disease under
study. Furthermore, when evaluating a new diagnostic test, it
must be compared to a reference standard, although the
latter is usually not perfect. In daily practice diagnostic tests
are not used in isolation. Several issues will influence the
interpretation of their results. First, clinicians have a prior
assumption about the patient’s chances of having the
disease under investigation, based on the patient’s
characteristics, symptoms, and the disease prevalence in
similar populations. Second, diagnostic tests are usually part
of a diagnostic strategy. Therefore, it is not sufficient to
determine the accuracy of a single test; one also needs to
determine its additional value to the patient’s diagnosis,
treatment, or outcome as part of a diagnostic strategy.
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In a physician’s daily practice, the use of diagnostic tests is
common. Tests refer not only to laboratory assessments, but
also to medical history, observing signs and symptoms, and
imaging techniques. However, tests are prone to errors;
sometimes diagnoses are missed when test results are
negative, but the opposite (a positive test result in the
absence of disease) may also occur. To be able to decide
whether it is useful to perform a test and how to interpret its
outcome, it is important to have information on the quality
of the test.
There are multiple aspects in the evaluation of a test, for
example its reproducibility, that is if the same test is done
again will it produce the same result; its accuracy, that is the
amount of agreement between the results from the diagnostic
test under study and those from a reference test; and its
additional value to a diagnostic strategy, that is will the
implementation of the diagnostic test into the routine
package of diagnostic tests improve the patient’s diagnosis,
treatment, and his or her outcome. This paper will focus on
the latter two aspects of a test, namely the different measures
of accuracy, their interpretation, and drawbacks, and on its
role within the diagnostic strategy.
DIFFERENT MEASURES OF ACCURACY
Diagnostic accuracy refers to the amount of agreement
between the results from the diagnostic test under study
and those from a reference test.1 Several issues are important
to determine the accuracy, and therefore multiple different
measures have been developed.1 For the illustration of all
the concepts, we used an example from a study evaluating
a laboratory test for detecting microalbuminuria in morning
urine samples.2 In this study, the general population
responded to an invitation for a screening test. As a
reference, a person was considered to have microalbuminuria
if the urine albumin excretion determined by nephelometry
exceeded 2.3 mg/l. All definitions and formulas are shown
in Table 1, as are specific results for this test to
detecting microalbuminuria, which are also presented in
Figure 1.
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Table 1 | The definition of the different measures of accuracy of a diagnostic and their application to a test diagnosing
microalbuminuria2
Reference standarda or ‘truth’
Target conditionb No target condition Total
Index testc result Positive TP
130
FP
357
487
Negative FN
23
TN
2017
2040
Total 153 2374 2527
Term Formula Results Definition
Sensitivity TP/(TPþ TN) 130/(130þ 23)¼ 85% Probability of a positive test result among those
having the target condition
Specificity TN/(TNþ FP) 2017/(2017þ 357)¼ 85% Probability of a negative test result among those
without the target condition
PPV TP/(TPþ FP) 130/(130þ 357)¼ 27% Probability of having the target condition given a
positive test result
NPV TN/(FNþ TN) 2017/(2017þ 153)¼ 99% Probability of not having the target condition given
a negative test result
Percent (positive) agreement (TPþ TN)/Total (130þ 2017)/2527¼ 85% The percentage of patients correctly qualified
Positive likelihood ratio Sensitivity/(1Specificity) 0.85/(10.85)¼ 5.7 Amount of certainty gained after a positive test result
Negative likelihood ratio (1Sensitivity)/Specificity (10.85)/0.85¼ 0.18 Amount of certainty gained after a negative test result
Pre-test probability of disease (TPþ TN)/Total (130þ 23)/2527¼ 6.1% Prevalence of disease in a population
Pre-test odds Prevalence/(1Prevalence) 0.061/(10.061)¼ 0.064 Odds of disease before performing a test
Post-test odds Odds of disease after test result
After a positive test result Pre-test oddspositive
likelihood ratio
0.064 5.7¼ 0.37 Odds of disease after a positive test result
After a negative test result Pre-test oddsnegative
likelihood ratio
0.064 0.18¼ 0.012 Odds of disease after a negative test result
Post-test probability of disease Probability of disease after test result
After a positive test result Post-test odds/(post-test oddsþ 1) 0.37/(0.37þ 1)¼ 26.9% Probability of disease after a positive test result
After a negative test result Post-test odds/(post-test oddsþ 1) 0.012/(0.012þ 1)¼ 1.14% Probability of disease after a negative test result
FN, false negative; NPV, negative predictive value; PPV, positive predictive value; TP, true positive.
aThe best available method for establishing the presence or absence of the target condition. bDisease or other health status. c(New) Diagnostic test under study.
Total population
2527
False positives
True positives
True negatives
All positive
test results
(487)
130
All those with
the disease
(153)
All positive test results (909)
All those with the disease
(758)
False negatives23
265
114
15042017
357
644
Figure 1 | Venn diagram of the dependency of true positive, true negative, false negative, false negative, and false positive results
in a test for microalbuminuria. Venn diagram of the distribution of the true positive, false negative, and false positive results for a test to
detect microalbuminuria (sensitivity 85%, specificity 85%) in a population of 2527 individuals of whom 6% have the disease (a), and in a
similar size population of whom 30% have the disease (b).2
1258 Kidney International (2009) 75, 1257–1263
a b c o f e p i d e m i o l o g y KJ van Stralen et al.: Diagnostic methods I
A perfect test will show a positive result for all those who
have the target condition (for example, the disease or other
health outcomes). Its ability to do this is described by its
sensitivity.3 Sensitivity is the proportion of all patients with
the disease (true positivesþ false negatives) who indeed have
a positive test result (true positives). However, a high
sensitivity alone does not make a test a good test. The test
also needs to be negative for all those without the disease.
This ability is expressed by the specificity of the test. It is the
proportion of all patients without the disease and a negative
test result (true negatives) of all those without the disease
(true negativesþ false positives).
In the study evaluating the diagnostic accuracy of the
microalbuminuria test, the sensitivity and specificity were
also calculated. Out of the 153 patients with microalbumi-
nuria, 130 had a positive test result with the urine test under
study, resulting in a sensitivity of 85% (130/153). Of the 2374
individuals without microalbuminuria, 2017 had a negative
urine test, resulting in a specificity of 85% (2017/2374).
In daily practice, the clinician and the patient will be more
interested in the positive (PPV) and negative predictive value
(NPV).4 The PPV indicates the probability of having the
disease after a positive test result, whereas the NPV is the
probability of not having the disease after a negative test
result (Table 1). So, when we use the earlier example, the
urine test showed a positive result in 487 persons, of whom
130 actually had microalbuminuria. Therefore, the PPV was
27% (130/487); that is, among those with a positive test
result, 27% actually had microalbuminuria. The urine test
was negative in 2040 patients, of whom 2017 did not have
microalbuminuria. Therefore, the NPV was 99%. On the
basis of these predictive values of this or other tests, the
physician may decide to perform additional tests, start a
treatment, or send the patient home.
Determine which accuracy is acceptable and whether one
prefers a higher specificity but lower sensitivity or vice versa is
not straightforward. Although values close to 100% are ideal,
there are situations in which one could prefer a test with a
lower sensitivity or specificity over another with a higher
sensitivity or specificity. Sometimes a new test is a triage, that is
will be used before a second test, and only those patients with a
positive result in the triage test will continue in the testing
pathway. For such a test, one may accept a lower accuracy than
that of the existing tests, as this triage test is not meant to
replace the second test. For example, in detecting chronic
kidney disease, an inexpensive dipstick test could be preferred
as a triage test, allowing many individuals to be tested. In this
test, it is important that all patients with chronic kidney disease
have a positive test result (high sensitivity), whereas the
number of patients with false-positive results (low specificity) is
considered somewhat less important, as they would be
identified using a second and the subsequent tests.
Another situation in which a diagnostic test with a lower
sensitivity and specificity could be preferred is when the test
with the better accuracy has a high risk of complications. For
example, as performing renal arteriography to test for renal
artery stenosis is an invasive diagnostic method, with
potential complications, one could prefer to replace arterio-
graphy with Doppler testing, which has 89% sensitivity and
73% specificity.5 In this way, one may attempt to balance the
desirable and undesirable consequences of performing
different diagnostic tests.6
The sensitivity, specificity, PPV, and NPV together result
in four different measures, each indicating the accuracy of the
test. All these measures have different pros and cons, and they
may be difficult to interpret.7,8 Therefore, one sometimes
prefers a combination of them. Frequently used parameters
are the percentage of patients correctly qualified, the
likelihood ratio, and the pre- and post-test probability. The
percentage of patients correctly qualified is the number of
concordant individuals, that is those with a positive test with
the diseaseþ those with a negative test without the disease
(true positives and true negatives in Table 1, respectively),
divided by the total population tested. So in the test for
microalbuminuria, 2147 (130þ 2017) out of 2527 indivi-
duals were correctly classified, resulting in a correctly
classified percentage of 85%. This parameter is easy to
understand and can be used when there are multiple
categories. A disadvantage is that when there are a large
number of individuals without the disease, as in our example,
the proportion correctly qualified is determined mainly by
the specificity and not by the sensitivity.
The likelihood ratio of a positive test result reflects the
amount of certainty of having the disease that is gained after
positive test reflects result, whereas the likelihood ratio of a
negative test result is the amount of certainty gained of not
having the disease with a negative test result. The positive
likelihood ratio can be calculated by dividing the sensitivity by
1specificity. It could be interpreted as ‘in patients with
microalbuminuria, a positive test is found 5.7 times as often as
in patients without microalbuminuria.’ The negative likelihood
ratio on the other hand is the amount of information that is
gained after a negative test result. It is calculated by
1sensitivity divided by the specificity. A likelihood ratio close
to 1 indicates that performing the test provides little additional
information regarding the presence or absence of the disease.
The likelihood ratios have the advantage of putting equal
weights to the sensitivity and specificity and therefore being less
dependent on the proportion of individuals under study who
are diseased versus non-diseased.
One could also compare the pre- and post-test probability
of a disease. The pre-test probability is equal to the
prevalence of the disease in the population under study.
The post-test probability is the chance of the disease after a
positive (or negative) test result. For example, the prevalence
or pre-test probability for an individual to have micro-
albuminuria was 6%. Using the calculation in Table 1, after a
positive test-result, we could estimate that the post-test
probability was equal to 27%. This number is equal to the
PPV. Likewise, after a negative test result, the chance of
having the disease decreased to a post-test probability of 1%
(which is equal to 1NPV).
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SOURCES OF BIAS AND VARIATION
Many diagnostic tests have been introduced with great
enthusiasm because of their high sensitivity and specificity,
but have nevertheless been rejected at a later stage. One of the
reasons for this rejection was that measures of accuracy of a
diagnostic test have often been presented as inherent and
fixed properties, whereas in reality, they can be affected by
different sources of variation and bias.9 We will now discuss
some of the important sources of variation.
Reference standard
To determine the measures of accuracy of a test, we need to
compare the test result with a reference standard that reflects
‘the truth’, that is, that can tell us with great certainty whether
or not the patient has the disease. Ideally, this reference
standard is an existing test with a sensitivity and specificity of
100%. As reference standards, similar to other tests, can be
costly, invasive, or impractical, one may sometimes want to
use the newly developed diagnostic test instead of the
reference standard.
When performing a diagnostic accuracy study, it may be
considered unethical to apply the reference standard to
someone who is asymptomatic, for example performing a
biopsy in transplant patients without rejection symptoms to
identify a new test for determining acute renal failure.10 In
this situation, only cases with a strong indication of rejection,
for example those with a positive result using the new
diagnostic test, will receive a biopsy. As not all patients are
tested with the reference standard, the number of patients
with a false-negative result is too low, resulting in an
overestimation of the sensitivity of the new test. This has
been called workup or verification bias.11,12
Although the reference standard is considered the best
available test at a certain moment, it will most likely not have
a sensitivity and specificity of 100%. Therefore, additional
information is needed. A first solution is to combine multiple
less accurate tests. Together, these tests could provide a
sufficient reference standard.13 A second solution is to use an
expert-based reference standard. A group of experts will then
decide whether a patient has the disease. However, this may
be subject to bias if the experts have their opinion based on
the outcome of one or more diagnostic tests.11 A third
solution is to follow those patients with a negative test result
in time to test whether they develop the disease later in life.
This has, for example, been done in the diagnosis of
pulmonary embolism.14 In summary, frequently, a reference
standard with a perfect sensitivity and specificity is unavail-
able, and in those cases, the measures of accuracy of a new
diagnostic test can only be compared with an imperfect
standard, resulting in incorrect estimates of the measures of
accuracy of the new test.
Case mix and disease severity
It is known for a long time that both the case mix and the
disease severity can affect the measures of diagnostic accuracy
of a test. One could study the sensitivity and specificity of
C-peptide levels to classify diabetes patients as type I or type
II in patients with kidney failure. However, as the kidney is
the major site of C-peptide metabolism and excretion,15 one
can easily imagine finding a different sensitivity and
specificity in a patient population with an altered kidney
function, compared with the results in a diabetic population
without chronic kidney disease.16,17 Consequently, when
comparing results between populations with varying rates of
kidney failure one would find different values for the
sensitivity and specificity. Situations similar to this occur
often, and in general for many tests it can be conceivable that
one could obtain different sensitivities and specificities in
women versus men, for elderly versus younger individuals
and in patients with and without (kidney) disease. For this
reason, it is needed to present strata-specific estimates of the
measures of disease accuracy for relevant subgroups.18,19
Also, the stage of disease severity could affect the
sensitivity and specificity of a test. Sherwood20 showed a
different sensitivity for renal ultrasound in patients with
different renal masses, that is he found a sensitivity of 97%
for predicting a renal cyst but that of 60% for detecting a
renal carcinoma. In general, the measures of accuracy can be
affected by the type of renal disease, stage of cancer, or level
of glomerular filtration rate and so on. Therefore, specifica-
tion of the sensitivity and specificity of the test for each
severity of a disease is needed.11
This shows that tests may perform differently in different
groups of subjects and for different severities of disease.
Therefore as a clinician, it is important to compare the
patient to be tested with the general characteristics or case-
mix of the study population described in a paper to see to
what extent the test properties provided in that paper apply
to this specific patient.1
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Figure 2 | Effect of population prevalence on the values of
positive and negative predictive values, using a test with a
sensitivity and specificity of 85%.
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Population prevalence
A feature of PPV and NPV is their dependence on the prior
probability of the disease (which is equal to the prevalence of
disease in the population to be tested).21 As is shown in
Figure 1 and Figure 2, if the disease prevalence increases, a
positive test result will have a higher PPV. This is due to a
relative decrease in the number of patients with a false-
positive result to the number of true positives. As a
consequence, the proportion of true positives among the
total number of those with a positive test result will rise,
resulting in a higher PPV. The opposite will occur for NPV,
that is a higher disease prevalence will result in a lower NPV.
Therefore, when comparing diagnostic accuracy measures
between different populations, different results can be
obtained. For example, in the microalbuminuria test with a
population prevalence of nearly 6%, the PPV was 27%
whereas the NPV was 99%. If the prevalence would have been
higher, for example when studying a predialysis population
in which 30% could have microalbuminuria, the PPV would
have increased to 71%, whereas the NPV would have
decreased to 93% (test results as shown in Figure 1b). A
similar variation of PPV and NPV, as a result of variation in
population prevalence, occurs when one would compare the
results of this test across, for example, different ethnicities,
different causes of renal disease, and different sexes.
BAYES’ THEOREM
When a young woman is presented to a nephrologist with
fever, fatigue, and proteinuria, the nephrologist is likely to
test for systemic lupus erythematosus (SLE). If a nuclear
antibody test (sensitivity 94%, specificity 97%) would
confirm the disease, the physician would probably accept
the diagnosis. In addition, if the test would be negative, it is
likely that the nephrologist will perform additional tests, as
this patient with classical symptoms has a high prior risk for
SLE. Conversely, when an old man is presenting with the
same symptoms, when having a negative test result, the
patient will be considered negative for SLE, as he has a much
lower prior chance of disease. When this patient would have a
positive test result, most physicians would still not be fully
convinced of the diagnosis.
As this example shows, the interpretation of the results of
a diagnostic test not only depends on the accuracy, the
sensitivity, and specificity, but also on the prior chance of
having the disease. This has been called the Bayes’ theorem. A
physician could estimate the prior chance of SLE in this
young woman to be around 50%. After a positive test result,
by using the formula from Table 1, her post-test probability
of the disease has increased from around 50% to nearly 97%.
On the other hand, in the man, the pretest probability of the
disease can be estimated by the physician to be closer to 5%.
Therefore, after a positive test result, his chance of having the
disease is still only 62%, which is much lower than that in the
young woman.
This also explains why multiple diagnostic tests are needed
when screening the general population. When this very good
nuclear antibody test would be used to screen the US
population for SLE (prevalence 33/100,000 individuals),
approximately 9 million individuals would test positive, of
whom only 1% have the disease. Although the posterior
probability for a single individual in this screening test after a
positive test result has increased from 0.03 to 1%, it is still
unlikely that this person truly has SLE, making screening
using a single diagnostic test not an efficient method.22
DIAGNOSTIC STRATEGY
Besides the accuracy of a test and the clinician’s interpretation of
the result, it is also important to know whether adding this test
to the current diagnostic strategy will improve the patient’s
diagnosis, treatment, and outcome.6,23 Most test results will
have an incremental value on top of each other, and a test may
be of value even if there exist other more accurate tests.12 A new
test could be added to the existing diagnostic strategy in three
ways.24 First, as a triage, the new test could be implemented
before the existing test, and only patients with a positive result
would continue to the existing testing pathway. Triage test may
be less accurate, but a very high sensitivity is important.
Preferably, when using a triage test, one prevents performing the
more expensive or time-consuming second test in everyone.
Instead, one selects only those who are at a high risk. An
example of a triage test is a dipstick test for microalbuminuria
to detect chronic kidney disease. Second, a new test may be
needed to replace an existing test. In this situation, the new test
may, for example, be more accurate, less invasive, or easier to
do. In this regard, one may think of examples like replacement
of the angiography by the Doppler ultrasound. Finally, a new
test may be added to a diagnostic strategy to improve the overall
diagnosis. In this situation, the new test needs to increase the
overall sensitivity of the diagnosis, which is probably at the
expense of the specificity.
Therefore, when developing a diagnostic test, one should
not only determine and compare the accuracy of a new test
with that of the old one and the reference standard, but also
study the new test as part of the routine package of tests. This
gives the possibility to determine the downstream con-
sequences of using a diagnostic test for outcome measures,
such as overall mortality, time to discharge, or cost-
effectiveness. Besides the type of tests that are performed,
the order in which the tests are performed also could be
important.25 Furthermore, one could calculate the post-
diagnostic strategy—the chance of disease by multiplying the
post-test probabilities of the different individual tests.
The ideal way to determine the effect of the new strategy is
to perform a randomized controlled trial, with one group
having the ‘old strategy’ for diagnosing the disease and the
other having the ‘new strategy’ involving the new test.12 In this
way, it is possible to determine the effect of the new therapy on
the treatment outcome and the cost-effectiveness of the
diagnostic strategy. An example of such a trial is the study
on the usefulness of b-type natriuretic peptide in the diagnosis
of congestive heart failure. Earlier studies had shown
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approximately similar sensitivity and specificity for those with
and without chronic kidney disease.26 However, when the
additional value of b-type natriuretic peptide measurement as
a ‘triage’ to the diagnostic strategy was studied as shown in
Figure 3, results were different.27 Using this randomized
controlled trial it was shown that adding the b-type natriuretic
peptide test was efficient in those without chronic kidney
disease, but inefficient in those with chronic kidney disease.
This indicates that although a test can have measures of
accuracy that are very high, this does not necessarily imply that
adding them to the current diagnostic strategy will improve a
patient’s diagnosis, treatment, and/or outcome.
CONCLUSION
Sensitivity and specificity are measures to assess the accuracy
of a diagnostic test. In recent years, several guidelines have
been published on how to report on diagnostic tests, which
are recommended for further reading.6,28 In this paper, we
explained the different measures of accuracy. For their
calculation, one needs a reference standard. However, as
very few tests are perfect, often an imperfect reference is used.
Furthermore, due to several biases and sources of variation,
such as differences in case mix, and disease severity, the
measures of accuracy cannot be considered as fixed proper-
ties of a diagnostic test.
In addition, the measures of accuracy are not isolated
instances. In general, clinicians have a prior assumption
about the patient’s chances of disease based on the patient’s
characteristics, symptoms, and disease prevalence. This will
influence the posterior chance of the disease. Furthermore, as
nearly all tests are performed within a range of tests, one
needs to consider the additional value of a new test on top of
or as replacement for the current diagnostic strategy,
especially with respect to the patient’s diagnosis, treatment,
and outcome.
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